Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of CD19/CD20 Dual CAR-T Cells in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma(B-NHL)

NCT04697290 is registered in ClinicalTrials.gov with Beijing Tsinghua Chang Gung Hospital as lead sponsor.

NCT NCT04697290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04697290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of CD19/CD20 Dual CAR-T Cells in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma(B-NHL)
Lead sponsor
Beijing Tsinghua Chang Gung Hospital
Phase
Phase 1
Overall status
Suspended
Start date
March 10, 2022
Completion date
June 10, 2023
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin's lymphoma